Citations

Showing 10 of 108152 citations.

Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use
Kwun, Jean , Matignon, Marie , Manook, Miriam , Guendouz, Soulef , Kheav, David, Poullot, Elsa , Gautreau, C., Ezekian, Brian , Bodez, Diane, Damy, T., Faivre, Laureline, Menouch, Dehbia, Park, Jae Berm , Belhadj, Karim , Chen, Dongfeng , Bilewski, Alyssa M., Yi, John S. , Collins, Bradley H. , Stegall, Mark D. , Farris, Alton B. , Grimbert, Philippe , Stegall, Mark, Stegall, Mark D , Farris, Alton B , Audard, Vincent , Menouche, Dehbia , Yoon, Janghoon , Knechtle, Stuart J.

Mayo Clinic

Journal of the American Society of Nephrology | June 21, 2019 | Volume: 30 | Issue: 7 | Pages: 1206-1219

10.1681/asn.2018121254 | PMID 31227636 Get It

Significance Statement Targeting plasma cells to reduce the risk of antibody-mediated rejection and decreased allograft survival due to anti-HLA donor-specific antibodies has not been explored in transplantation. After sensitizing eight rhesus macaques with two sequential mismatched skin allografts, the authors desensitized four with daratumumab (anti-CD38 mAb) and plerixafor (anti-CXCR4) before transplant. Compared with controls, the daratumumab-treated animals had significantly reduced donor-specific antibody levels and prolonged renal graft survival; however, this reduction was not maintained. Two patients treated with daratumumab—one with therapy-resistant acute kidney antibody-mediated rejection and a highly sensitized heart transplant candidate—exhibited a significant decrease in class 1 and 2 donor-specific antibodies that led to clinical improvement of antibody-mediated rejection and heart graft access. These findings suggest daratumumab merits investigation as a potential therapeutic strategy, although further research is needed. Background Donor-specific antibodies are associated with increased risk of antibody-mediated rejection and decreased allograft survival. Therefore, reducing the risk of these antibodies remains a clinical need in transplantation. Plasma cells are a logical target of therapy given their critical role in antibody production. Methods To target plasma cells, we treated sensitized rhesus macaques with daratumumab (anti-CD38 mAb). Before transplant, we sensitized eight macaques with two sequential skin grafts from MHC-mismatched donors; four of them were also desensitized with daratumumab and plerixafor (anti-CXCR4). We also treated two patients with daratumumab in the context of transplant. Results The animals treated with daratumumab had significantly reduced donor-specific antibody levels compared with untreated controls (57.9% versus 13% reduction; P <0.05) and prolonged renal graft survival (28.0 days versus 5.2 days; P <0.01). However, the reduction in donor-specific antibodies was not maintained because all recipients demonstrated rapid rebound of antibodies, with profound T cell–mediated rejection. In the two clinical patients, a combined heart and kidney transplant recipient with refractory antibody-mediated rejection and a highly sensitized heart transplant candidate, we also observed a significant decrease in class 1 and 2 donor-specific antibodies that led to clinical improvement of antibody-mediated rejection and to heart graft access. Conclusions Targeting CD38 with daratumumab significantly reduced anti-HLA antibodies and anti-HLA donor-specific antibodies in a nonhuman primate model and in two transplant clinical cases before and after transplant. This supports investigation of daratumumab as a potential therapeutic strategy; however, further research is needed regarding its use for both antibody-mediated rejection and desensitization.
First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1
Somaiah, Neeta , Block, Matthew S. , Kim, Joseph W. , Shapiro, Geoffrey I. , Khanh, T. , Hwu, Patrick , Jones, Robin L. , Meulen, Jan H. ter, Bohac, Chet, Hsu, Frank J., Gnjatic, Sacha , Gnjatic, Sacha , Jones, Robin L , Shapiro, Geoffrey I , Hwu, Patrick , Eder, Joseph P. , Lu, Hailing , Chen, Michael , Pollack, Seth M.

Mayo Clinic

Clinical Cancer Research | June 21, 2019 | Volume: 25 | Issue: 19 | Pages: 5808-5817

10.1158/1078-0432.ccr-19-1025 | PMID 31227504 Get It

Abstract Purpose: LV305 is a modified, third-generation, nonreplicating, integration-deficient lentivirus-based vector designed to selectively transduce dendritic cells in vivo. LV305 induces expression of the New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) cancer testis antigen in dendritic cells, promoting immune responses against NY-ESO-1–expressing tumors. This phase I study evaluated the safety, immunogenicity, and preliminary efficacy of LV305 in patients with sarcoma or other solid tumors. Patients and Methods: Adults with previously treated, advanced, NY-ESO-1–positive solid tumors and limited tumor burden were eligible. LV305 was administered every 3 weeks by intradermal injection in four dose cohorts (Cohort 1: 108 vector genomes (vg) x 3 doses; Cohorts 1A, 2, and 3: 108 vg, 109 vg, 1010 vg x 4 doses). Results: Thirty-nine patients were enrolled: 3 patients each in Cohorts 1, 1A, and 2, and 30 patients in Cohort 3. No dose-limiting toxicities were observed. Tumor types included sarcoma (n = 24), ovarian (n = 8), melanoma (n = 6), and lung cancer (n = 1). All treatment-related adverse events were grade 1 or 2. Common treatment-related adverse events were fatigue (49%), injection site reactions (46%), and myalgia (21%). The disease control rate was 56.4% in all patients and 62.5% in sarcoma patients. One patient with synovial sarcoma achieved a partial response lasting &gt;36 months. Anti–NY-ESO-1-specific CD4+ and/or CD8+ T cells were induced in 57% of evaluable sarcoma patients. Induction of an anti–NY-ESO-1 immune response was associated with improved 1-year survival in an exploratory analysis. Conclusions: This first-in-class, first-in-human study of LV305 demonstrated a favorable safety profile, induction of antigen-specific responses, and potential clinical activity in patients with advanced cancer.
Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma
Personett, Heather A. , Frazee, Erin N. , McCullough, Kristen , Dierkhising, Ross , Leung, Nelson , May, Heather P. , Frazee, Erin N , McCullough, Kristen B , Leung, Nelson , Habermann, Thomas M.

Mayo Clinic

Leukemia & Lymphoma | June 21, 2019 | Volume: 60 | Issue: 9 | Pages: 2271-2277

10.1080/10428194.2019.1574000 | PMID 31223041 Get It

Epicardial access: Adjusting the approach as we discover complications
Vaidya, Vaibhav R. , Asirvatham, Samuel J. , Asirvatham, Samuel J

Mayo Clinic

Journal of Cardiovascular Electrophysiology | June 21, 2019 | Volume: 30 | Issue: 8 | Pages: 1341-1344

10.1111/jce.14036 | PMID 31222891 Get It

Postoperative venous thromboembolism and mortality in patients with pancreatic surgery
Majmudar, Kaushal , Quintero, Luis Diaz , Fuentes, Harry E , Stocker, Susan J. , Tafur, Alfonso , Lee, Cheong , Talamonti, Mark S. , Quintero, Luis D , Stocker, Susan , Talamonti, Mark , Fuentes, Harry E

Mayo Clinic

Journal of Surgical Oncology | June 21, 2019 | Volume: 120 | Issue: 3 | Pages: 494-500

10.1002/jso.25589 | PMID 31222842 Get It

Abstract Background and Objectives Pancreatic cancer is strongly associated with thrombosis. We investigated early postoperative venous thromboembolism (PVTE) mortality among patients with pancreatic surgery and compared outcomes in adenocarcinoma pancreatic cancer (ACPC) to non‐adenocarcinoma pancreatic neoplasm (NACPN). Methods We analyzed a prospectively collected database of patients who underwent pancreatic cancer or neoplasm‐related surgery. As NACPN is underrepresented in other studies, we selected NACPN patients and a random sample of ACPC patients. PVTE was defined as VTE occurring within 3 months of surgical intervention. Statistical analysis was performed using Cox proportional hazards regression. Results A total of 441 pancreatic surgery patients were included, with 331 ACPC and 110 NACPN. Median follow‐up was 449 days during which 90 (20.4%) patients developed VTE. PVTE occurred in 53 (12.0%) patients, including 41 (12.4%) ACPC patients and 12 (10.9%) NACPN patients. Those with PVTE had 60% higher mortality rate. A multivariable analysis found that PVTE is an independent predictor of increased mortality (HR Adj, 1.6; 95% CI, 1.1‐2.2; P < .01). The mortality impact was not consistent between ACPC (HR, 3.2; 95% CI, 1.3‐7.9) and NACPN groups (HR, 1.3; 95% CI, 0.9‐1.8). Conclusions Postoperative venous thromboembolism is an independent predictor of increased mortality in pancreatic surgery, specifically in adenocarcinoma pancreatic cancer surgery.
A Viable Alternative When Propensity Scores Fail: Evaluation of Inverse Propensity Weighting and Sequential G-Estimation in a Two-Wave Mediation Model
MacKinnon, David P. , Mazza, Gina L. , MacKinnon, David P , Mazza, Gina L , Valente, Matthew J.

Mayo Clinic

Multivariate Behavioral Research | June 21, 2019 | Volume: 55 | Issue: 2 | Pages: 165-187

10.1080/00273171.2019.1614429 | PMID 31220937 Get It

Implementation of a patient blood management program in hematopoietic stem cell transplantation (Editorial, p. 2763)
Warner, Matthew A. , Jambhekar, Nilesh S., Saadeh, Salwa , Jacob, Eapen K., Kreuter, Justin D. , Mundell, William C., Marquez, Alberto , Higgins, Andrew , Madde, Nageswar R., Kor, Daryl J. , Higgins, Andrew A, Warner, Matthew A , Higgins, Andrew A., Hogan, William J.

Mayo Clinic

Transfusion | June 21, 2019 | Volume: 59 | Issue: 9 | Pages: 2840-2848

10.1111/trf.15414 | PMID 31222775 Get It

BACKGROUNDRecipients of hematopoietic stem cell transplantation (HSCT) are among the highest consumers of allogeneic red blood cell (RBC) and platelet (PLT) components. The impact of patient blood management (PBM) efforts on HSCT recipients is poorly understood.STUDY DESIGN AND METHODSThis observational study assessed changes in blood product use and patient‐centered outcomes before and after implementing a multidisciplinary PBM program for patients undergoing HSCT at a large academic medical center. The pre‐PBM cohort was treated from January 1 through September 31, 2013; the post‐PBM cohort was treated from January 1 through September 31, 2015.RESULTSWe identified 708 patients; 284 of 352 (80.7%) in the pre‐PBM group and 225 of 356 (63.2%) in the post‐PBM group received allogeneic RBCs (p < 0.001). Median (interquartile range [IQR]) RBC volumes were higher before PBM than after PBM (3 [2‐4] units vs. 2 [1‐4] units; p = 0.004). A total of 259 of 284 pre‐PBM patients (91.2%) and 57 of 225 (25.3%) post‐PBM patients received RBC transfusions when hemoglobin levels were more than 7 g/dL (p < 0.001). The median (IQR) PLT transfusion quantities was 3 (2‐5) units for pre‐PBM patients and 2 (1‐4) units for post‐PBM patients (p < 0.001). For patients with PLT counts of more than 10 × 109/L, a total of 1219 PLT units (73.4%) were transfused before PBM and 691 units (48.8%) were transfused after PBM (p < 0.001). Estimated transfusion expenditures were reduced by $617,152 (18.3%). We noted no differences in clinical outcomes or transfusion‐related adverse events.CONCLUSIONPatient blood management implementation for HSCT recipients was associated with marked reductions in allogeneic RBC and PLT transfusions and decreased transfusion‐related costs with no detrimental impact on clinical outcomes.
Paediatric and adult bronchiectasis: Specific management with coexisting asthma, COPD, rheumatological disease and inflammatory bowel disease
Maglione, Marco , Aksamit, Timothy R. , Santamaria, Francesca , Aksamit, Timothy

Mayo Clinic

Respirology | June 21, 2019 | Volume: 24 | Issue: 11 | Pages: 1063-1072

10.1111/resp.13615 | PMID 31222879 Get It

ABSTRACTBronchiectasis, conventionally defined as irreversible dilatation of the bronchial tree, is generally suspected on a clinical basis and confirmed by means of chest high‐resolution computed tomography. Clinical manifestations, including chronic productive cough and endobronchial suppuration with persistent chest infection and inflammation, may deeply affect quality of life, both in children/adolescents and adults. Despite many cases being idiopathic or post‐infectious, a number of specific aetiologies have been traditionally associated with bronchiectasis, such as cystic fibrosis (CF), primary ciliary dyskinesia or immunodeficiencies. Nevertheless, bronchiectasis may also develop in patients with bronchial asthma; chronic obstructive pulmonary disease; and, less commonly, rheumatological disorders and inflammatory bowel diseases. Available literature on the development of bronchiectasis in these conditions and on its management is limited, particularly in children. However, bronchiectasis may complicate the clinical course of the underlying condition at any age, and appropriate management requires an integration of multiple skills in a team of complementary experts to provide the most appropriate care to affected children and adolescents. The present review aims at summarizing the current knowledge and available evidence on the management of bronchiectasis in the other conditions mentioned and focuses on the new therapeutic strategies that are emerging as promising tools for improving patients’ quality of life.
Estimates of the prevalence of speech and motor speech disorders in persons with complex neurodevelopmental disorders
Shriberg, Lawrence D., Jakielski, Kathy J., Mabie, Heather L. , Strand, Edythe A.

Mayo Clinic

Clinical Linguistics & Phonetics | June 20, 2019 | Volume: 33 | Issue: 8 | Pages: 707-736

10.1080/02699206.2019.1595732 | PMID 31221012 Get It

Ultrasound‐Guided Percutaneous Peripheral Nerve Stimulation for the Treatment of Lower Extremity Pain: A Rare Case Report
Ferreira‐Dos‐Santos, Guilherme , Hurdle, Mark Friedrich B., Gupta, Sahil , Clendenen, Steven R. , Clendenen, Steven R

Mayo Clinic

Pain Practice | June 20, 2019 | Volume: 19 | Issue: 8 | Pages: 861-865

10.1111/papr.12810 | PMID 31220401 Get It

AbstractObjectiveThis case report presents an application of percutaneous peripheral nerve stimulation to the right superficial peroneal nerve to treat a patient with chronic intractable L5–S1 radiculopathy pain that conventional treatment failed to ameliorate.MethodsThe patient underwent an uneventful implantation of a percutaneous peripheral nerve stimulator. The implanted lead (15 cm in length and 1.2 mm in diameter) containing the receiver coil and 3 stimulation electrodes (Bioness Stimrouter®, Valencia, CA, U.S.A.) was implanted parallel with the trajectory of the right superficial peroneal nerve.ResultsTwo weeks after implantation of the percutaneous peripheral nerve stimulator, the patient experienced excellent pain relief and reported a significant increase in mobility. At the 3‐month follow‐up consultation, the patient reported maintenance of the reduction of pain in his right lower extremity as well as improved performance in his daily activities.ConclusionPercutaneous peripheral nerve stimulation offers an alternative treatment option for intractable pain associated with chronic radiculopathy, especially for patients in whom conventional treatment options have been exhausted. Further clinical series involving larger numbers of patients are warranted in order to assess the definitive role of percutaneous peripheral nerve stimulation for the treatment of chronic intractable radiculopathy pain.